4.7 Review

Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 70, Issue 14, Pages 1760-1776

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2017.08.037

Keywords

aspirin; cangrelor; clopidogrel; prasugrel; ticagrelor; vorapaxar

Funding

  1. Spanish Ministry of Science and Innovation [PNS 2015-71653-R]
  2. FEDER funds
  3. U.K. Medical Research Council
  4. Amgen
  5. AstraZeneca
  6. Bayer AG
  7. Merck Sharp and Dohme
  8. Bayer Healthcare
  9. Boehringer Ingelheim
  10. Bristol-Myers Squibb
  11. Daiichi-Sankyo
  12. Servier
  13. Boston Scientific
  14. Merck
  15. Bayer
  16. Novartis
  17. Pfizer
  18. Sanofi
  19. Eli Lilly
  20. Guerbet Medical
  21. Medtronic
  22. Cordis
  23. Stago
  24. Centocor
  25. Fondation de France
  26. INSERM
  27. Federation Francaise de Cardiologie
  28. Societe Francaise de Cardiologie
  29. Celgene
  30. Daiichi-Sankyo Italia
  31. Novartis Farma
  32. GlaxoSmithKline
  33. Roche Diagnostics International
  34. PlaqueTec
  35. Actelion/Idorsia
  36. Avacta
  37. Bristol-Myers Squibb/Pfizer
  38. Thermo Fisher Scientific
  39. The Medicines Company
  40. MRC [MC_U137686853, MC_UU_12026/6, MC_UU_12026/5] Funding Source: UKRI
  41. Medical Research Council [MC_UU_12026/6, MC_UU_12026/5, MC_U137686853] Funding Source: researchfish

Ask authors/readers for more resources

Antiplatelet drugs provide first-line antithrombotic therapy for the management of acute ischemic syndromes (both coronary and cerebrovascular) and for the prevention of their recurrence. Their role in the primary prevention of atherothrombosis remains controversial because of the uncertain balance of the potential benefits and risks when combined with other preventive strategies. The aim of this consensus document is to review the evidence for the efficacy and safety of antiplatelet drugs, and to provide practicing cardiologists with an updated instrument to guide their choice of the most appropriate antiplatelet strategy for the individual patient presenting with different clinical manifestations of coronary atherothrombosis, in light of comorbidities and/or interventional procedures. (C) 2017 by the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available